PARP1 inhibitor
PARP1 inhibitor has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, May 9, 2024: “Converting cell death into senescence by PARP1 inhibition improves recovery from acute oxidative injury”.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Centre National de la Recherche Scientifique and 6 more
- Animals1
What did studies of PARP1 inhibitor find?
2Studies of PARP1 inhibitor measured 2 outcomes; the most studied are cellular senescence (1 study) and necrosis (1).
Cellular senescence
upin mice1upin mouse cells1
1 study
Cellular senescence
upin mice1upin mouse cells1
PARP1 inhibitor increases cellular senescence in mice.
“PARP inhibition reduces necrosis and increases transient senescence at the injury site”
Animalsin kidney ischemia-reperfusion damagekidney
Nature aging
PARP1 inhibitor induces cellular senescence in mouse cells.
“blocking PARP1 activation promotes conversion of cell death into senescence (CODIS).”
Cellsunder high oxidative stress
Nature aging
Necrosis
downin mice1
1 study
Necrosis
downin mice1
PARP1 inhibitor decreases necrosis in mice.
“PARP inhibition reduces necrosis and increases transient senescence at the injury site”
Animalsin kidney ischemia-reperfusion damagekidney
Nature aging